Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

被引：2

作者：

Pipe, Steven ^{[1
]}

Collins, Peter ^{[2
]}

Dhalluin, Christophe ^{[3
]}

Kenet, Gili ^{[4
,5
]}

Schmitt, Christophe ^{[3
]}

Buri, Muriel ^{[3
]}

Jimenez-Yuste, Victor ^{[6
]}

Peyvandi, Flora ^{[7
,8
]}

Young, Guy ^{[9
]}

Oldenburg, Johannes ^{[10
]}

Mancuso, Maria Elisa ^{[11
,12
]}

Kavakli, Kaan ^{[13
]}

Kiialainen, Anna ^{[3
]}

Chang, Tiffany ^{[14
]}

Lehle, Michaela ^{[3
]}

Niggli, Markus ^{[3
]}

Fijnvandraat, Karin ^{[15
]}

机构：

[1] Univ Michigan, Ann Arbor, MI 48109 USA

[2] Cardiff Univ, Sch Med, Cardiff, Wales

[3] F Hoffmann La Roche Ltd, Basel, Switzerland

[4] Sheba Med Ctr, Ramat Gan, Israel

[5] Tel Aviv Univ, Tel Aviv, Israel

[6] Univ Autonoma Madrid, La Paz Univ Hosp Idi Paz, Madrid, Spain

[7] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Milan, Italy

[8] Univ Milan, Milan, Italy

[9] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA

[10] Univ Bonn, Bonn, Germany

[11] IRCCS Humanitas Res Hosp, Rozzano, Italy

[12] Humanitas Univ, Rozzano, Italy

[13] Ege Univ, Fac Med, Childrens Hosp, Izmir, Turkiye

[14] Spark Therapeut Inc, San Francisco, CA USA

[15] Univ Amsterdam, Amsterdam, Netherlands

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-177963

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[11] Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
Schmitt, Christophe
Adamkewicz, Joanne I.
Xu, Jin
Petry, Claire
Catalani, Olivier
Young, Guy
Negrier, Claude
Callaghan, Michael U.
Levy, Gallia G.
THROMBOSIS AND HAEMOSTASIS, 2021, 121 (03) : 351 - 360
[12] Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience
Callaghan, Michael
Trzaskoma, Benjamin
Ko, Richard H.
Lee, Lucy
Patel, Anisha M.
Tzeng, Eunice
Shah, Michelle Lynn
Chang, Tiffany Y.
Niggli, Markus
Dhalluin, Christophe
Mahlangu, Johnny
BLOOD, 2019, 134
[13] Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors
Castaman, Giancarlo
Peyvandi, Flora
Hovinga, Johanna A. Kremer
Schutgens, Roger E. G.
Robson, Susan
Moreno, Katya
Jimenez-Yuste, Victor
TH OPEN, 2024, 08 (01) : e42 - e54
[14] A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors
Escobar, Miguel
Bullano, Michael
Mokdad, Ali G.
Caicedo, Jorge
Schultz, Bob G.
Fan, Qi
Verma, Sumit
EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (06) : 467 - 474
[15] Factor VIII Use in the Treatment of Breakthrough Bleeds in People with Moderate or Mild Hemophilia A without Factor VIII Inhibitors Receiving Emicizumab Prophylaxis: The Phase III HAVEN 6 Experience
Jimenez-Yuste, Victor
Lim, Elise
Mistry, Ketna
Ventriglia, Giuliana
Shapiro, Amy D.
BLOOD, 2023, 142
[16] Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial
Pipe, Steven W.
Collins, Peter
Dhalluin, Christophe
Kenet, Gili
Schmitt, Christophe
Buri, Muriel
Jimenez-Yuste, Victor
Peyvandi, Flora
Young, Guy
Oldenburg, Johannes
Mancuso, Maria Elisa
Kavakli, Kaan
Kiialainen, Anna
Deb, Sonia
Niggli, Markus
Chang, Tiffany
Lehle, Michaela
Fijnvandraat, Karin
BLOOD, 2024, 143 (14) : 1355 - 1364
[17] Emicizumab use in females with moderate or mild hemophilia A without factor VIII inhibitors who warrant prophylaxis
Hermans, Cedric
Ventriglia, Giuliana
Obaji, Samya
Beckermann, Benjamin M.
Lehle, Michaela
Catalani, Olivier
d'Oiron, Roseline
Frenzel, Laurent
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (08)
[18] COST-CONSEQUENCE ANALYSIS OF EMICIZUMAB PROPHYLAXIS FOR SEVERE HEMOPHILIA A PATIENTS WITHOUT INHIBITORS
Cortesi, P. A.
Castaman, G.
Mantovani, L. G.
VALUE IN HEALTH, 2020, 23 : S696 - S696
[19] Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study
Kiialainen, Anna
Niggli, Markus
Kempton, Christine L.
Castaman, Giancarlo
Chang, Tiffany
Paz-Priel, Ido
Adamkewicz, Joanne, I
Levy, Gallia G.
HAEMOPHILIA, 2022, 28 (06) : 1033 - 1043
[20] Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia A with Inhibitors: Results from the HAVEN 2 Study
Young, Guy
Liesner, Ri
Sidonio, Robert F., Jr.
Oldenburg, Johannes
Jimenez-Yuste, Victor
Mahlangu, Johnny
Kruse-Jarres, Rebecca
Wang, Michael
Chang, Tiffany
Uguen, Marianne
Doral, Michelle
Schmitt, Christophe
Levy, Gallia G.
Shima, Midori
Mancuso, Maria Elisa
BLOOD, 2018, 132

← 1 2 3 4 5 →